

Table S1. Characteristics of patients with cutaneous chronic graft versus host disease (cGVHD) (n = 20)

No.	Sex/age at transplantation, years	Diagnosis	Donor and graft source	Type of cutaneous cGVHD	Extent of cutaneous involvement	Cutaneous features of cGVHD	Time interval from lichenoid to sclerotic rash, months	Additional dermatological findings	Therapy	Cutaneous response/systemic therapy
1	M/5	OP	MUD, BM	De novo	Localized to photo-exposed areas	Lichenoid	-	Photo-distribution of rash	Topical	Yes
2	F/7	AML	MUD, BM	De novo	Localized	Lichenoid	-	-	Topical	Yes
3	F/4	ALCL	MSD, BM	Progressive	Widespread	Lichenoid and then sclerotic	8	Keratoderma	Topical, UVA1	Yes
4	M/10	CML	MUD, BM	Progressive	Widespread	Lichenoid and then sclerotic	8	Keratoderma, scarring alopecia	Topical, NB UVB, UVA1, ECP, systemic	No/prednisone, tacrolimus
5 ^a	F/15	AML	MSD, BM	De novo	Localized to the scalp	Lichenoid	-	Scarring alopecia	Topical, systemic	Death
6	M/0	HES	MSD, BM	De novo	Localized to the scalp	Lichenoid	-	Scarring alopecia	Topical	Yes
7	F/7	HLH	MUD, BM	Progressive	Widespread	Lichenoid and then sclerotic	13	Keratoderma	Topical, NB UVB, UVA1, ECP, systemic	No/prednisone, IV lidocaine, MTX
8	M/14	ALL	MUD, BM	Progressive	Widespread	Lichenoid and then sclerotic	11	Eccrine poroma	Topical, ECP, systemic	Yes/prednisone, MMF, tacrolimus
9	M/15	ALL	MSD, BM	De novo	Localized to the face and upper trunk	Atopic dermatitis-like	-	-	Topical	Yes
10	M/3	AML	MRD, BM	De novo	Widespread	Lichenoid and then sclerotic	N/A	Keratoderma, scarring alopecia	Topical, NB UVB, systemic	No/prednisone
11 ^a	M/8	NB	MUD, PBSC	Progressive	Widespread	Lichenoid	-	-	Systemic	Death
12	M/7	ALL	MUD, PBSC	Progressive	Localized to the face and upper trunk	Lichenoid	-	-	Topical, systemic	Rejection of graft
13	M/19	AML	MSD, PBSC	De novo	Widespread	Lichenoid	-	-	Topical, ECP, systemic	- ^b
14	M/10	ALL	MSD, PBSC	Progressive	Widespread	Lichenoid and then sclerotic, erosions	N/A	Scarring alopecia	Topical, ECP, systemic	No/prednisone, cyclosporine, MMF, imatinib, MSC
15	M/18	ALL	MSD, PBSC	De novo	N/A	Lichenoid	-	-	ECP, systemic	- ^b
16 ^a	M/11	ALL	MSD, PBSC	De novo	Widespread	Lichenoid	-	-	Topical, ECP, systemic	Death
17	M/18	ALL	MSD, PBSC	De novo	Localized to the face and upper chest	Lichenoid	-	Photo-distribution of rash	Topical, ECP, systemic	- ^b
18	F/5	ALL	MSD, PBSC	De novo	Widespread	Lichenoid	-	-	Topical, systemic	LFU
19	F/6	ALL	MUD, PBSC	Progressive	Localized to the limbs	Lichenoid	-	-	Topical, ECP, systemic	Yes
20	F/8	ALL	MSD, PBSC	Progressive	Localized to the limbs, trunk and scalp	Ichthyosiform	-	-	Topical, ECP, systemic	Yes

^aThese patients died. ^bIn these patients systemic therapies were required for involvement of other organs, such as gastrointestinal tract, liver and lungs, and their cutaneous disease was mild or less clinically relevant. ALL: anaplastic large cell lymphoma; ALCL: acute lymphoblastic leukaemia; AML: acute myeloid leukaemia; BM: bone marrow; cGVHD: chronic graft versus host disease; CML: chronic myeloid leukaemia; ECP: extracorporeal photopheresis; HES: hypereosinophilic syndrome; HLH: haemophagocytic lymphohistiocytosis; IV: intravenous; LFU: loss of follow-up; MRD: HLA-matched non-sibling relative donor; MMF: mycophenolic acid; MSC: mesenchymal stem cells; MSD: HLA-matched sibling donor; MTX: methotrexate; MUD: HLA-matched unrelated donor; N/A: non-applicable; NB: neuroblastoma; NB UVB: narrow-band ultraviolet B; OP: osteopetrosis; PBSC: peripheral blood stem cell; UVA1: ultraviolet A1.